Geron extends Pharmakon loan draw deadline to July 30, 2026; $125M already funded

GERON CORP

First Amendment extends Tranche B ($75M) and Tranche C ($50M) request deadline from Dec 31, 2025 to July 30, 2026.
Makewhole Date for prepayment extended from Nov 1, 2026 to May 1, 2027.
Tranche A of $125M funded Nov 1, 2024; total facility remains up to $250M.
Prepayment premiums unchanged: 3% before 3rd anniversary, 2% thereafter, 1% before maturity.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

GERON CORP amended First Amendment to Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership valued at Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3 (effective 2026-01-05).

Action: amendment
Agreement: credit facility
Counterparty: BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership
Value: Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3
Effective: 2026-01-05

Exact text from the filing

On January 5, 2026, Geron Corporation ("we" or the "Company") entered into that certain first amendment to loan agreement (the "First Amendment Agreement") with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a "Lender"), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent (the "Agent"), which amends the terms of that certain Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement", and as amended by the First Amendment Agreement, the "Amended Loan Agreement), by and among the Company, the Lenders and the Agent.

View on SEC.gov

324 material agreements filed in the last 30 days. Browse all material agreements →

GERON CORP filing history →

Source: SEC EDGAR

accession 0001193125-26-003388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.